PAC1フォスファテーゼは,アポトーシスと成長抑制のシグナル伝達においてp53の転写標的である
Yuxin Yin1, Yu-Xin Liu, Yan J Jin
1Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032, USA.
Nature
|April 4, 2003
まとめ
腫瘍抑制剤p53は,アポトーシス中にフォスファターゼPAC1 (二重特異性フォスファターゼ2) を活性化させます. PAC1はp53媒介によるアポトーシスと腫瘍抑制に不可欠であり,新しい遺伝子調節機構を明らかにしています.
科学分野:
- 分子生物学は分子生物学である.
- 細胞生物学 細胞生物学
- がん研究 がん研究
背景:
- 腫瘍抑制タンパク質p53は,標的遺伝子の転写制御を通じて細胞プロセスを調節する.
- PAC1 (活性細胞のフォスファタゼ1) は,DUSP2としても知られており,MAPキナーゼを非活性化する二重フォスファタゼです.
研究 の 目的:
- PAC1転写の調節におけるp53の役割を調査する.
- PAC1を含むp53媒介アポトーシスのメカニズムを解明する.
- 腫瘍抑制におけるPAC1の機能を調査する.
主な方法:
- PAC1プロモーター活動とp53結合の分析.
- 小さな干渉RNA (siRNA) を使用して,PAC1の発現を減らす.
- PAC1の過剰発現に関する研究
- MAPキナーゼの活性度の測定. MAPキナーゼ活性度の測定. MAPキナーゼの活性度の測定. MAPキナーゼの活性度の測定.
主要な成果:
- p53は,そのプロモーターのパリンドロミックサイトに結合することによって,PAC1転写を直接活性化します.
- p53によるPAC1誘導は,血清欠乏と酸化ストレス下で発生し,アポトーシスを引き起こします.
- siRNA媒介によるPAC1の減少はp53誘発のアポトーシスを抑制し,PAC1の過剰発現はアポトーシスを強化し,腫瘍形成を抑制する.
- p53の活性化により,MAPキナーゼの活性が抑制され,このプロセスにはPAC1が必要かつ十分である.
結論:
- p53は,特定のストレス条件下で新しい結合部位を通じてPAC1の転写を調節する.
- PAC1は,p53-依存アポトーシスと腫瘍抑制の重要な媒介である.
- パリンドロミックなp53結合部位の特定は,p53の遺伝子調節機構の洞察を提供します.
キーワード:
非プログラム的なものです.関連する概念動画
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...


